Zelira Therapeutics - Global Leader in cannabinoid-based medicine

Zelira Therapeutics Ltd is a leading global cannabinoid-based biopharmaceutical company with access to the world’s largest and fastest growing markets. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets. The Company is focused on developing branded cannabinoid-based medicines for the treatment of a variety of medical conditions in its Rx business, including insomnia, autism and chronic non-cancer pain.
Patient

We’re here to help you access alternative treatment options

Patients
Doctors + Specialists

Supporting healthcare professionals and patients with cannabinoid-based medicines

Doctors + Specialists
Pharmacists

Supporting healthcare professionals and patients with cannabinoid-based medicines

Pharmacists

Recent Video and Audio from Zelira Therapeutics

Investor Webinar: HOPE® 1 SPV created to fund Ph.2 and Ph.3 US FDA trials
February 22, 2023
Investor Webinar: HOPE® 1 SPV created to fund Ph.2 and Ph.3 US FDA trials

Chairman Osagie Imasogie and CEO Oludare Odumosu lead a presentation on the creation of an SPV and US $8.6M cornerstone funding from Cantheon Capital LLC for HOPE 1 Ph.2 and Ph.3 US FDA clinical trials.

November 17, 2022
Zelira AGM Presentation 2022

Zelira Therapeutics Chairman Osagie Imasogie and Global CEO Oludare Odumosu present a company update at the 2022 Annual General Meeting.

November 15, 2022
Zelira CEO Oludare Odumosu speaks with Proactive

Zelira Global CEO Oludare Odumosu provides Proactive with an update on the company’s progress with its proprietary revenue-generating products, global expansion and its pipeline of candidates undergoing clinical development.

September 7, 2022
Zelira Therapeutics Investor Presentation – Sept 2022

Hear the latest business updates from Zelira Therapeutics Chairman Osagie Imasogie and Global CEO Dr Oludare Odumosu.

May 12, 2022
Zelira Therapeutics Investor Presentation

Zelira Therapeutics Chairman Osagie Imasogie and Global CEO Dr Oludare Odumosu deliver a slide presentation and answer investor questions as part of a business update.

February 27, 2022
Channel 7 News Perth

Zelira product helping young patient with autism spectrum disorder

Contact Us

    Follow Zelira Therapeutics

    Subscribe

      Zelira Therapeutics
      Level 3, 101 St Georges Terrace, Perth WA 6000
      Phone +61 8 6558 0886

      Copyright © Zelira Therapeutics. All rights reserved. | Disclaimer.

      Start typing and press Enter to search

      View more
      Shopping Cart